Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
South African Press Association - August 5, 2009
He said HIV/Aids was a syndrome that in some cases required people to already start taking medication in their 20s.
That meant some patients could end up using the drug for as long as 50 years.
Motsoaledi expressed concern about the unknown side effects of such long exposure to the drugs.
"Should the generic industry not be investing more in post-marketing? It is not an additional expenditure but an investment," he said.
Motsoaledi made the remark in a speech read out on his behalf by Anban Pillay, chief director of financial planning at the Health Ministry, at a conference on generic medicine in Sandton, Johannesburg.
The minister lamented the triple burden of disease on South Africa and said the worldwide outbreak of swine flu was making matters worse.
"The H1N1 virus adds to this [burden]," said Motsoaledi.
The triple burden of disease referred to communicable diseases, chronic diseases, and violence and injuries.
He said all South Africans had the right to quality healthcare. South Africans had become too used to seeing long medicine queues at state hospitals.
"Every person must have access to essential medicine," the minister said.
Motsoaledi was scheduled to address the conference himself but cancelled late on Tuesday night due to an extended Cabinet meeting.
Another conference on generic medicine was being hosted in Sun City this week.
At the latter event, Vikash Salig, CEO of Dr Reddy's Laboratories, warned against lower-grade or incorrect concentrations of active pharmaceutical ingredients in generic medicine.
He said the Medicines Control Council (MCC) recently reported on this happening, referring specifically to anti-tuberculosis drugs used in the public sector.
"Generic medicines are a safe and effective alternative to originator drugs for South Africa," said Salig.
"The incorrect use of raw materials has been addressed by the MCC. All companies (both generic and innovator) have to provide comprehensive documentation when changing a source of raw material."
090805
SA090802
Copyright © 2009 - South African Press Association. Reproduction of this article (other than one copy for personal reference) must be cleared through the South African Press Association, Cotswold House, Greenacres Office Park, Cnr. Victory & Rustenburg Roads, VICTORY PARK, PO BOX 7766, JOHANNESBURG, 2000; Fax No: +27 11 782-1587/8, Tel No: +27 11 782-1600.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .